Losartan Potassium Active Pharmaceutical Ingredient (API) Global Market Report 2025

The losartan potassium active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to factors such as the growing adoption of antihypertensive drugs, the rising incidence of lifestyle-related disorders, increased awareness of cardiovascular health, higher global healthcare expenditure, and the growing demand for affordable generic medications.

The losartan potassium active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to factors such as an expanding patient population with chronic illnesses, a growing emphasis on preventive cardiovascular care, increased healthcare service penetration in emerging markets, advancements in drug formulation technologies, and rising government initiatives to promote generic drugs. Key trends during this period include advancements in manufacturing processes, the development of advanced drug delivery systems, the creation of pediatric-friendly formulations, innovations in packaging for extended shelf life, and the development of combination therapies involving losartan.

The rising prevalence of hypertension is expected to drive the growth of the losartan potassium active pharmaceutical ingredient (API) market. Hypertension is a condition characterized by persistently high blood pressure, which increases the risk of heart disease, stroke, and other serious health complications. The growing incidence of hypertension is largely attributed to diets high in salt and processed foods, which contribute to fluid retention and increased strain on the heart. Losartan potassium helps control hypertension by blocking angiotensin II, a hormone that constricts blood vessels. By relaxing and widening blood vessels, losartan potassium lowers blood pressure and reduces the workload on the heart. For instance, in January 2024, the American Heart Association reported that 131,454 deaths were primarily linked to high blood pressure in 2022, a rise from 124,508 deaths in 2021. As a result, the increasing prevalence of hypertension is fueling the growth of the losartan potassium API market.

Companies in the losartan potassium API market are focusing on developing innovative products to enhance patient compliance and precision in dosing, such as losartan potassium oral suspension. This liquid form of losartan potassium is designed for patients who have difficulty swallowing tablets. For example, in March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, received FDA approval for Arbli, a ready-to-use liquid formulation for hypertension treatment, stroke risk reduction in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy in type 2 diabetes patients. Arbli offers precise dosing without the need for compounding and comes in a 165 mL peppermint-flavored suspension (10 mg/mL) with an 18-month shelf life at room temperature.

In April 2025, Scienture Holdings Inc., a US-based pharmaceutical company, formed a partnership with Saptalis Pharmaceuticals LLC to manufacture Arbli (losartan potassium) Oral Suspension, 10 mg/mL. The collaboration includes warehousing and distribution agreements to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in hypertension treatment. Saptalis Pharmaceuticals LLC, a US-based pharmaceutical company, specializes in developing and distributing losartan potassium formulations.

Major players in the losartan potassium active pharmaceutical ingredient (API) market are Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals Ltd, Lupin Ltd, Zydus Lifesciences Ltd, Alkem Laboratories Ltd, IPCA Laboratories Ltd, Alembic Pharmaceuticals Ltd, Granules India Limited, Vasudha Pharma Chem Ltd, IOL Chemicals and Pharmaceuticals Limited, Unichem Laboratories Ltd, Global Pharma Tek, Hetero Drugs Ltd, Manus Aktteva Biopharma LLP, Wellona Pharma, Atom pharma, Sinoway Industrial Co. Ltd, Cerata Pharmaceuticals LLP.

North America was the largest region in the losartan potassium API market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in losartan potassium active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the losartan potassium active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Losartan potassium active pharmaceutical ingredient (API) refers to the pure compound used in the formulation of losartan-based medications, which are primarily used to treat high blood pressure and protect kidney function. It mainly helps manage hypertension, reduces the risk of heart attacks, and preserves kidney function in diabetic patients.

The main product forms of losartan potassium API include tablets, capsules, and others. Tablets are the most commonly used oral form, valued for their ease of use, affordability, and precise dosing in managing hypertension. It is produced through various methods such as synthetic routes, biotechnological processes, and continuous flow production. Distribution channels include online pharmacies, hospital pharmacies, retail pharmacies, and others. Losartan potassium is used for a range of conditions, including hypertension, heart failure, chronic kidney disease, and more. It is employed by various end-users, such as hospitals, clinics, home care settings, and pharmaceutical companies.

The losartan potassium API market research report is one of a series of new reports that provides losartan potassium API market statistics, including the losartan potassium API industry global market size, regional shares, competitors with the losartan potassium API market share, detailed losartan potassium API market segments, market trends, and opportunities, and any further data you may need to thrive in the losartan potassium API industry. This losartan potassium API market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The losartan potassium active pharmaceutical ingredient (API) market consists of sales of bulk powder, granules, injectable concentrates, and pre-formulated intermediates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.